Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.
Dal Maso A, Lorenzi M, Ferro A, Pilotto S, Cecere F, Follador A, Polo V, Del Conte A, Sartori G, Giavarra M, Scattolin D, Indraccolo S, Frega S, De Maglio G, Menis J, Bonanno L, Calabrese F, Guarneri V, Conte P, Pasello G.
Dal Maso A, et al. Among authors: de maglio g.
Future Oncol. 2021 Jul;17(19):2513-2527. doi: 10.2217/fon-2021-0356. Epub 2021 May 14.
Future Oncol. 2021.
PMID: 33988036